Bayer’s Nubeqa (darolutamide) Receives MHLW’s Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

 Bayer’s Nubeqa (darolutamide) Receives MHLW’s Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Bayer’s Nubeqa (darolutamide) Receives MHLW’s Approval for Men with Non-Metastatic Castration-Resistant Prostate Cancer

Shots:

  • The approval is based on P-III ARAMIS study assessing Nubeqa (600mg, qd) + ADT vs PBO + ADT in 1,509 patients in a ratio (2:1) with nmCRPC
  • The P-III ARAMIS study results: improvement in 1EPs of MFS (40.4mos. vs 18.4mos.); MFS is supported by delay in time to pain progression and other 2EPs i.e, time to cytotoxic CT, time to SSE
  • Nubeqa is an Ari, co-developed by Bayer and Orion Corporation, being evaluated in P-III ARASENS study for m-hormone-sensitive PC and an approved therapy in the US and Brazil and is underway in EU and other regions

Click here ­to­ read full press release/ article | Ref: Bayer | Image: BioSpace

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post